{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260825797512/en/Celea-Therapeutics-Will-Present-Phase-3-Trial-Design-for-Idiopathic-Pulmonary-Fibrosis-and-Key-Insights-from-a-Deupirfenidone-Drug-Drug-Interaction-Study-at-the-Upcoming-European-Respiratory-Society-ERS-Congress", "message": "News view counter 900723 successfully enlarged"}